In Transition? Bayer Exercises Option To Up Stake In JV With Zydus
Executive Summary
Bayer is increasing its holding in its long-standing joint venture with Zydus Cadila in India by 25%, sparking off some speculation on the alliance’s future trajectory.
You may also be interested in...
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Bayer’s Zieler On The Power Of Real World Data, Asia Pacific Outlook
Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, tells Scrip why real world data is “very powerful” as more stakeholders including physicians look beyond just randomized clinical trial data. Zieler also underscores the German multinational’s intent to give “special attention” to the fast-growing Asia Pacific region.